Array BioPharma To Present Clinical Data On ARRY-797 At The 2012
American College Of Rheumatology Annual Meeting
BOULDER, Colo., Nov. 6, 2012 /PRNewswire/ -- Array BioPharma Inc.
(NASDAQ: ARRY) announced that an abstract discussing the final
Phase 2 trial results with ARRY-797 in patients with osteoarthritis
pain will be presented at the 2012 American College of Rheumatology
Annual Meeting in Washington, D.C.
This abstract includes data on ARRY-797's analgesic effect and
markers of disease modification. In addition, biomarkers of
cartilage (COMP) and bone (CTX‑I) degradation were assessed.
ARRY‑797 treatment resulted in statistically significant decreases
in COMP and CTX‑I at week 4 (decreases of 10% and 38% versus
placebo, respectively). The decrease in CTX‑I was sustained and
returned to baseline by the follow‑up visit. The abstract
concludes that further evaluation of the potential for disease
modifying activity is warranted.
(Logo:
http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)
The abstract can be accessed through the American College of
Rheumatology Annual Meeting website,
http://www.rheumatology.org/apps/MyAnnualMeeting/ExploreMeeting.
After the presentation, the poster will be available as a PDF
on Array's website at www.arraybiopharma.com.
Poster:
|
|
A
Randomized, Placebo-Controlled Phase 2 Study of ARRY-797 in
Patients with Osteoarthritis Pain Refractory to NSAID Treatment
Showed Statistically Significant Improvements in WOMAC Pain and in
Biomarkers of Bone and Cartilage Degradation
|
Session:
|
|
Late
Breaking Abstracts
|
Date:
|
|
Tuesday,
November 13, 2012
|
Time:
|
|
9:00 -
11:00 AM Eastern Time
|
Location:
|
|
Walter E.
Washington Convention Center - Poster Hall (Hall B)
|
Array announced in July 2012 that
ARRY-797, a non-opioid, met its primary endpoint in a randomized,
placebo-controlled and active-controlled (oxycodone ER) Phase 2
clinical trial in 157 osteoarthritis patients suffering from
moderate to severe knee pain despite the use of non-steroidal
anti-inflammatory drugs (NSAIDs). Patients in all treatment
groups continued using NSAIDs throughout the trial. ARRY-797 is a
novel, oral, selective p38 inhibitor with a mechanism of action
unique from that of currently approved pain medications.
Given our internal focus on hematology/oncology, Array is in active
discussions with potential partners to maximize the value of this
drug.
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small‑molecule drugs to treat
patients afflicted with cancer. Array is evolving into a late-stage
development company, with two wholly‑owned programs, ARRY-614 and
ARRY-520, and three partnered programs, selumetinib (with
AstraZeneca), MEK162 (with Novartis), and danoprevir (with
InterMune / Roche), having the potential to begin Phase 3 or
pivotal trials by the end of calendar year 2013. For more
information on Array, please go to www.arraybiopharma.com.
Forward-Looking Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
about the timing of the announcement of the results of clinical
trials and the development plans for ARRY-797, expectations that
events will occur that will result in greater value for the
Company, the potential for the results of ongoing preclinical and
clinical trials to support regulatory approval or the marketing
success of ARRY-797, and our ability to partner ARRY-797for
up-front fees, milestone and/or royalty payments and to maximize
the value for Array. These statements involve significant risks and
uncertainties, including those discussed in our most recent annual
report filed on Form 10-K, in our quarterly reports filed on Form
10-Q, and in other reports filed by Array with the Securities and
Exchange Commission. Because these statements reflect our current
expectations concerning future events, our actual results could
differ materially from those anticipated in these forward-looking
statements as a result of many factors. These factors include, but
are not limited to, our ability to continue to fund and
successfully progress internal research and development efforts and
to create effective, commercially viable drugs; risks associated
with our dependence on our collaborators for the clinical
development and commercialization of our out-licensed drug
candidates; the ability of our collaborators and of Array to meet
objectives tied to milestones and royalties; our ability to
effectively and timely conduct clinical trials in light of
increasing costs and difficulties in locating appropriate trial
sites and in enrolling patients who meet the criteria for certain
clinical trials; risks associated with our dependence on
third-party service providers to successfully conduct clinical
trials within and outside the United
States; our ability to achieve and maintain profitability
and maintain sufficient cash resources; the extent to which the
pharmaceutical and biotechnology industries are willing to
in-license drug candidates for their product pipelines and to
collaborate with and fund third parties on their drug discovery
activities; our ability to out-license our proprietary candidates
on favorable terms; and our ability to attract and retain
experienced scientists and management. We are providing this
information as of November 6, 2012.
We undertake no duty to update any forward-looking statements to
reflect the occurrence of events or circumstances after the date of
such statements or of anticipated or unanticipated events that
alter any assumptions underlying such statements.
CONTACTS:
|
Array
BioPharma Inc.
|
|
Tricia
Haugeto
|
|
(303)
386-1193
|
|
thaugeto@arraybiopharma.com
|
SOURCE Array BioPharma Inc.